The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.  The Medicines and ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

GlobalCapital presents the nominations for its Syndicated Loan, Leveraged Finance and Private Debt Awards 2025. The Awards, ...

The Global Immuno-oncology Clinical Trials Market is expanding steadily due to the rise in cancer incidence, rapid scientific progress in immunotherapy, and growing investments in precision oncology ...

GlobalCapital presents the nominations for its Syndicated Loan, Leveraged Finance and Private Debt Awards 2025. The Awards, ...